1
00:00:00,109 --> 00:00:04,109
Hello everyone, my name is Vamsi Upaduri
and I work as a senior statistical

2
00:00:04,109 --> 00:00:05,589
programmer at Gilead Science.

3
00:00:05,949 --> 00:00:10,349
Today I'll talk about the role of
statistical programming in accelerating

4
00:00:10,389 --> 00:00:12,229
clinical drug development process.

5
00:00:13,070 --> 00:00:16,899
Did you know that it can take
anywhere between 5 to 10 years and

6
00:00:16,910 --> 00:00:21,430
millions of dollars to bring a drug
from discovery stage to market?

7
00:00:22,360 --> 00:00:27,555
Today I'll discuss how statistical
programming Place a critical role in

8
00:00:27,575 --> 00:00:33,525
accelerating this process, transforming
the raw data into actionable insights to

9
00:00:33,605 --> 00:00:36,085
evaluate the drug safety and efficacy.

10
00:00:36,825 --> 00:00:41,505
With growing complexities in clinical
trial designs, increased data

11
00:00:41,514 --> 00:00:46,285
volumes, and stringent regulatory
requirements from agencies like FDA

12
00:00:46,325 --> 00:00:51,270
and EMEA, The robust statistical
programming has become essential.

13
00:00:52,060 --> 00:00:58,550
We'll explore its impact at every stage,
from managing and analyzing data, to

14
00:00:58,619 --> 00:01:04,769
ensuring regulatory compliance, ultimately
leading to faster and more effective

15
00:01:04,769 --> 00:01:07,100
treatments to improve patient outcomes.

16
00:01:07,600 --> 00:01:11,960
Let's explore the evolution of
tools in statistical programming

17
00:01:12,090 --> 00:01:15,920
and how they have transformed
clinical data analysis over time.

18
00:01:16,589 --> 00:01:22,660
SAS laid the foundation as a gold standard
with validated procedures, robust audit

19
00:01:22,670 --> 00:01:27,350
trials, and comprehensive documentation
to ensure regulatory compliance.

20
00:01:27,350 --> 00:01:33,684
R introduced flexibility and innovation,
providing advanced statistical modeling,

21
00:01:33,684 --> 00:01:40,280
high quality data visualizations,
and collaborative ecosystem of user

22
00:01:40,340 --> 00:01:45,080
contributed packages, making it
ideal for an exploratory analysis.

23
00:01:45,949 --> 00:01:50,500
Python revolutionized the field
with its integration of machine

24
00:01:50,500 --> 00:01:54,660
learning, automated workflows, and
powerful data processing tools.

25
00:01:55,080 --> 00:01:57,450
to support the real
world evidence analysis.

26
00:01:58,080 --> 00:02:02,890
Together, these tools help
programmers to address the increasing

27
00:02:02,890 --> 00:02:08,019
complexity of clinical trials
with precision and adaptability.

28
00:02:08,519 --> 00:02:10,654
Clinical programming plays a key role.

29
00:02:11,074 --> 00:02:16,594
critical role in providing data analysis
across all phases of clinical trials.

30
00:02:17,294 --> 00:02:22,254
In phase one, it analyzes the
safety data, identifies any

31
00:02:22,314 --> 00:02:26,864
adverse events, and determines
the dose tolerability of a drug.

32
00:02:27,584 --> 00:02:33,114
Phase two, focus on assessing the
safety and preliminary efficiency,

33
00:02:33,634 --> 00:02:35,954
efficacy in a small population.

34
00:02:36,594 --> 00:02:41,474
While phase 3 evaluates the
safety and confirms the efficacy

35
00:02:41,534 --> 00:02:43,164
in large patient groups.

36
00:02:43,964 --> 00:02:50,354
In phase 4, statistical programming
team monitors long term safety

37
00:02:50,404 --> 00:02:51,934
and real world effectiveness.

38
00:02:52,289 --> 00:02:57,129
by integrating real world data
and detecting any safety signals.

39
00:02:57,629 --> 00:03:03,719
Comprehensive statistical data analysis
ensures reliable trial outcomes by

40
00:03:03,969 --> 00:03:05,919
evaluating the safety and efficacy.

41
00:03:05,929 --> 00:03:11,844
And furthermore, The regulatory
standards are upheld by developing the

42
00:03:11,844 --> 00:03:18,544
STDM and ADaM datasets based on the
CD standards and generating TLFs as

43
00:03:18,574 --> 00:03:24,374
per the Statistical Analysis Plan to
ensure the data traceability, integrity,

44
00:03:24,584 --> 00:03:27,134
and seamless regulatory submissions.

45
00:03:27,634 --> 00:03:33,644
Statistical programming often bridges
the gap between the protocol and data

46
00:03:33,644 --> 00:03:38,404
analysis by converting the complex
protocol into precise programming

47
00:03:38,404 --> 00:03:43,484
specifications, ensuring the accurate
implementation of study endpoints.

48
00:03:43,859 --> 00:03:45,389
and analysis methods.

49
00:03:46,149 --> 00:03:52,109
Adaptive trial design leverage advanced
algorithms for dynamic sample size

50
00:03:52,109 --> 00:03:58,119
calculations and treatment allocations
enabling responsive trial modifications

51
00:03:58,359 --> 00:03:59,979
based on the accumulated data.

52
00:04:00,869 --> 00:04:06,649
Automated systems for safety monitoring
enables continuous surveillance tracking

53
00:04:06,689 --> 00:04:11,939
adverse events and conducting risk
benefit assessments with statistical

54
00:04:12,189 --> 00:04:14,289
outputs by data monitoring committee.

55
00:04:14,430 --> 00:04:21,089
Finally, a predefined interim analysis
will be performed to review the validated

56
00:04:21,089 --> 00:04:26,409
outputs generated by a statistical
programmer to make evidence based

57
00:04:26,459 --> 00:04:34,669
decisions to make sure the trial,
continuation or modification or a

58
00:04:34,979 --> 00:04:38,114
decision to early terminate the study.

59
00:04:38,614 --> 00:04:43,054
Regulatory compliance is the cornerstone
of any clinical data submissions,

60
00:04:43,574 --> 00:04:47,284
and standardized datasets play
a critical role in this process.

61
00:04:47,834 --> 00:04:54,124
STDM and ADaM datasets are developed
and validated to meet the stringent

62
00:04:54,204 --> 00:05:00,024
FDA and EMA requirements by following
the CD standards, implementation

63
00:05:00,024 --> 00:05:04,044
guidelines, and therapeutic area
specific guidance documents.

64
00:05:04,654 --> 00:05:09,844
For example, the requirements can
vary between significantly between

65
00:05:09,844 --> 00:05:11,584
the oncology and virology studies.

66
00:05:12,234 --> 00:05:15,804
Adhering to these guidelines
ensure alignment with

67
00:05:16,244 --> 00:05:17,844
evolving industry standards.

68
00:05:18,474 --> 00:05:21,004
Comprehensive submission
documents such as DEFINE.

69
00:05:21,004 --> 00:05:27,674
XML, STDM Data Reviewer's Guide, Analysis
Data Reviewer's Guide, facilitates a

70
00:05:27,674 --> 00:05:30,184
thorough submission regulatory assessment.

71
00:05:31,064 --> 00:05:37,714
Additionally, leveraging validation tools
like PNaCl 21 enables conformance checks.

72
00:05:38,014 --> 00:05:43,094
And ensure data integrity,
minimize risk and delays

73
00:05:43,404 --> 00:05:45,154
throughout the submission process.

74
00:05:45,654 --> 00:05:52,294
As clinical trial grows more complex,
leveraging innovative technologies is

75
00:05:52,294 --> 00:05:55,374
essential for efficiency and accuracy.

76
00:05:56,164 --> 00:06:01,154
AI and machine learning revolutionized
trials by automating the data

77
00:06:01,154 --> 00:06:06,504
cleaning process, reducing manual
errors, and using its predictive

78
00:06:06,514 --> 00:06:12,314
models to optimize the outcomes like
forecasting patient enrollment and

79
00:06:12,544 --> 00:06:14,484
identifying any patient reports.

80
00:06:15,204 --> 00:06:21,974
Cloud based platforms enables seamless
global collaboration with secure, scalable

81
00:06:21,984 --> 00:06:27,424
infrastructure, supporting the real time
data processing and integrated version

82
00:06:27,464 --> 00:06:30,074
control systems to prevent delays.

83
00:06:30,714 --> 00:06:35,264
Additionally, an interactive
and dynamic visualization tools.

84
00:06:35,339 --> 00:06:42,549
create dashboards for data safety
monitoring reviews, DSMB, to improve the

85
00:06:42,559 --> 00:06:49,249
regulatory submissions with graphs, which
enhances stakeholders communication.

86
00:06:49,729 --> 00:06:53,859
Together, these advancements
streamline the trial processes.

87
00:06:54,634 --> 00:07:00,134
and enable faster and more
informed decision making.

88
00:07:00,634 --> 00:07:03,504
Let's look at two
contrasting case studies.

89
00:07:04,044 --> 00:07:08,204
One demonstrating the success of
statistical programming during the

90
00:07:08,594 --> 00:07:11,284
rapid development of COVID 19 vaccines.

91
00:07:11,584 --> 00:07:15,254
And the other highlighting the
challenges in the regulatory compliance

92
00:07:15,734 --> 00:07:17,474
phase during an oncology trial.

93
00:07:18,034 --> 00:07:23,334
Together, these examples show the
critical, the statistical programming

94
00:07:23,374 --> 00:07:25,294
role place in the clinical trials.

95
00:07:25,794 --> 00:07:30,574
The COVID 19 vaccine development
showcased how advanced statistical

96
00:07:30,574 --> 00:07:36,494
programming can transform the clinical
trials using sophisticated adaptive trial

97
00:07:36,494 --> 00:07:39,094
designs and real time data analysis.

98
00:07:39,609 --> 00:07:45,009
researchers were able to reduce the
development timelines by significantly

99
00:07:45,039 --> 00:07:49,839
80 percent enabling simultaneous
phase 2 and phase 3 trials.

100
00:07:50,339 --> 00:07:54,219
Rolling regulatory submissions
further accelerated this process,

101
00:07:54,569 --> 00:07:58,319
submitting a new, setting a new
benchmark for its efficiency.

102
00:07:58,819 --> 00:08:03,549
On the other hand, a pharmaceutical
company faced a significant

103
00:08:03,549 --> 00:08:05,249
challenge with its oncology trial.

104
00:08:05,249 --> 00:08:10,259
A six month submission delay
occurred due to clinical CDISC

105
00:08:10,759 --> 00:08:13,649
failures, CDISC compliance failures.

106
00:08:13,959 --> 00:08:18,389
including inconsistencies in derived
variables and missing documentations.

107
00:08:19,219 --> 00:08:24,199
This highlights the critical importance
of robust statistical programming

108
00:08:24,899 --> 00:08:29,989
and stringent quality control to
ensure smooth regulatory submissions.

109
00:08:30,489 --> 00:08:36,374
As clinical trials grow more complex,
Adopting best practices in statistical

110
00:08:36,374 --> 00:08:42,704
programming is essential to ensure
efficiency, accuracy, and compliance.

111
00:08:43,254 --> 00:08:48,734
Successful programming involves
integration of expertise from protocol

112
00:08:48,744 --> 00:08:54,414
development all the way to the submission,
establishing series compliance templates,

113
00:08:54,579 --> 00:09:00,409
And automated workflows for process
standardization, performing systematic

114
00:09:00,409 --> 00:09:07,429
data validations at every milestone to
maintain quality assurance and investing

115
00:09:07,429 --> 00:09:12,179
in continuous training to stay up to
date with the regulatory standards and

116
00:09:12,189 --> 00:09:18,079
leveraging cutting edge tools like AI
to enhance the efficiency and accuracy.

117
00:09:18,669 --> 00:09:20,679
Together, these practices.

118
00:09:21,059 --> 00:09:27,259
form a comprehensive framework that drives
the success in drug development process.

119
00:09:27,759 --> 00:09:31,909
The future of statistical programming
is defined by four key directions.

120
00:09:32,499 --> 00:09:38,889
First, integrating real world evidence
data using AI powered analytics

121
00:09:39,189 --> 00:09:43,899
enables the seamless inclusion of
data from electronic health records,

122
00:09:44,169 --> 00:09:48,629
insurance claims, and patient
registries, providing deep insights

123
00:09:48,669 --> 00:09:51,329
into clinical treatment outcomes.

124
00:09:51,339 --> 00:09:51,399
Thank you.

125
00:09:51,974 --> 00:09:57,974
Second, the decentralized trials are
becoming increasingly important, relying

126
00:09:57,974 --> 00:10:05,364
on robust systems to validate and analyze
real time patient reported outcomes from

127
00:10:05,364 --> 00:10:11,274
its wearable device data, making clinical
research more accessible and flexible.

128
00:10:12,104 --> 00:10:16,064
Third, adopting open source tools like.

129
00:10:16,874 --> 00:10:23,094
R and Python fosters collaboration and
innovation while maintaining strict

130
00:10:23,094 --> 00:10:28,584
regulatory compliance and validation
standards to ensure high quality outputs.

131
00:10:29,004 --> 00:10:34,524
Finally, traceability is critical with
automated documentation and versioned

132
00:10:34,554 --> 00:10:39,564
environments ensuring that all the
analyses are transparent, replicable,

133
00:10:39,714 --> 00:10:41,844
and ready for regulatory review.

134
00:10:42,344 --> 00:10:48,454
As the landscape of clinical trials
evolves, regulatory bodies like FDA are

135
00:10:48,454 --> 00:10:54,014
modernizing clinical trial processes by
introducing innovative frameworks for

136
00:10:54,074 --> 00:10:57,164
complex trial design and master protocols.

137
00:10:57,954 --> 00:11:01,904
They are also developing comprehensive
guidelines to integrate real world

138
00:11:01,904 --> 00:11:08,133
evidence with a focus of deep quality
and validation and to establish standards

139
00:11:08,133 --> 00:11:14,184
for validating AI and machine learning
algorithms to ensure transparency,

140
00:11:14,684 --> 00:11:19,664
reproducibility, and support for
advanced analytics in clinical research.

141
00:11:20,164 --> 00:11:25,254
As we look ahead to the future of
clinical drug development, statistical

142
00:11:25,254 --> 00:11:30,634
programming remains a driving force
for innovation and efficiency.

143
00:11:30,984 --> 00:11:35,634
By continually evolving to meet new
challenges and adopting advanced

144
00:11:35,644 --> 00:11:41,029
technologies, the field ensures
faster, more cost effective trials.

145
00:11:41,529 --> 00:11:45,109
Collaboration between programmers,
researchers and regulators will be

146
00:11:45,169 --> 00:11:50,269
essential to overcome the complexities
paving the way for improved patient

147
00:11:50,329 --> 00:11:55,759
outcomes and the need to deliver the
life saving treatments worldwide.

148
00:11:56,319 --> 00:11:57,909
Thank you for attending the talk.

